Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial

被引：0

作者：

Sciurba, F. C. ^{[1
]}

Rheault, T. ^{[2
]}

Bengtsson, T. ^{[3
]}

Rickard, K. ^{[2
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[2] Verona Pharma Plc, Raleigh, NC USA

[3] Stat Mind AB, Lund, Sweden

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A5007

引用

页数：1

共 50 条

[21] Ensifentrine, A Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Provides Effective Bronchodilation in COPD When Administered Twice Daily Over 7 Days Via a Dry Powder Inhaler
Rheault, T.
Rickard, K.
Boscia, J. A.
Bengtsson, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[22] A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
Ferguson, Gary T.
Kerwin, Edward M.
Rheault, Tara
Bengtsson, Thomas
Rickard, Kathleen
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1137 - 1148
[23] Additional Bronchodilation by Ensifentrine, A Dual PDE3/4 Inhibitor, When Combined with a LAMA/LABA in Patients with Moderate to Severe COPD
Rickard, K.
Rheault, T.
Bengtsson, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[24] Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis
Watz, Henrik
Rickard, Kathleen
Rheault, Tara
Bengtsson, Thomas
Singh, Dave
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 2199 - 2206
[25] Bronchodilation and Symptom Improvement with Ensifentrine, A Dual PDE3/4 Inhibitor: Sub-Group Analyses of a Four Week Randomized, Controlled Trial in Patients with COPD
Rheault, T.
Rickard, K.
Bengtsson, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[26] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks
Mahler, D. A.
Bhatt, S. P.
Singh, D.
Rheault, T.
Reyner, D.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[27] ENSIFENTRINE, A DUAL PDE 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION IN PATIENTS WITH COPD WHEN ADMINISTERED TWICE DAILY OVER 7 DAYS VIA PMDI
Rheault, Tara
Singh, Dave
Leaker, Brian
Bengtsson, Thomas
Rickard, Kathleen
CHEST, 2021, 160 (04) : 1847A - 1848A
[28] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils
Sciurba, F. C.
Christenson, S.
Rheault, T.
Reyner, D.
Bengtsson, T.
Rickard, K.
Barjaktarevic, I.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[29] Safety of Ensifentrine, a Dual PDE3/4 Inhibitor: Results of Reported GI and CV Events from a Four Week Randomized, Controlled Trial
Rickard, K.
Rheault, T.
Bengtsson, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[30] Safety And Bronchodilator Effects Of Nebulized Rpl554, A Novel Dual Pde3/4 Inhibitor In COPD
Cazzola, M.
Calzetta, L.
Segreti, A.
Rogliani, P.
Page, C.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187

← 1 2 3 4 5 →